Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA is exploring a "competency-based approach" to regulate generative AI medical devices — think credentialing, but for algorithms. The agency released a discussion paper outlining pre- and post-market oversight strategies, comparing AI device performance to panels of qualified clinicians. It's still early days, but the FDA is signaling a major regulatory rethink is underway.
The FDA is taking a fresh look at how it regulates AI-powered medical devices, drawing inspiration from how doctors get credentialed. In a newly released discussion paper, the agency outlines a "competency-based approach" for evaluating generative AI (GenAI) medical devices — setting performance benchmarks and confirming real-world clinical performance, much like a physician would be assessed before practicing independently.
The push comes as AI-enabled health tools have exploded onto the clinical scene, ranging from diagnostic aids to devices that can deliver patient care with or without a doctor in the loop. The FDA acknowledges that GenAI devices are fundamentally different from traditional medical devices — their outputs vary and they evolve over time — making the existing regulatory framework a poor fit.
Key Takeaways:
Why it matters: With AI rapidly reshaping clinical care, how the FDA regulates these tools will have enormous implications for patient safety, innovation, and global regulatory standards. This discussion paper is the first step toward a framework that could set the tone for AI oversight worldwide.
